Pfizer US Pharm — Medicare Part D spending
Rank #11 by attributed Part D spend · 64 tracked drugs · CMS data year 2023
About $6,189,129,960 of Medicare Part D spending in 2023 is attributed to Pfizer US Pharm across the 64 of its drugs tracked here, ranking it #11 among manufacturers on this site. Its biggest Part D drug is Ibrance at $2,020,903,604. Attribution uses the CMS manufacturer lists and is indicative, not definitive. These are aggregate program figures, not the price you pay.
Source: CMS Medicare Part D Spending by Drug (data year 2023). Data as of June 2026.
Pfizer US Pharm drugs in Medicare Part D (2023)
| Brand | Generic | Total spend | Per dosage unit | Beneficiaries | Spend rank |
|---|---|---|---|---|---|
| <a href="/drug/ibrance-palbociclib/">Ibrance</a> | Palbociclib | $2,020,903,604 | $753.02 | 16,015 | #20 |
| <a href="/drug/vyndamax-tafamidis/">Vyndamax</a> | Tafamidis | $1,349,659,508 | $735.47 | 7,589 | #35 |
| <a href="/drug/abrysvo-rsv-vacc-pref-a-and-pref-b-pf/">Abrysvo</a> | Rsv Vacc, Pref A And Pref B/PF | $698,160,178 | $327.30 | 2,131,906 | #74 |
| <a href="/drug/xeljanz-xr-tofacitinib-citrate/">Xeljanz XR</a> | Tofacitinib Citrate | $585,772,572 | $191.75 | 12,497 | #94 |
| <a href="/drug/inlyta-axitinib/">Inlyta</a> | Axitinib | $466,771,314 | $250.67 | 4,739 | #115 |
| <a href="/drug/xeljanz-tofacitinib-citrate/">Xeljanz</a> | Tofacitinib Citrate | $279,993,121 | $94.17 | 6,936 | #171 |
| <a href="/drug/bosulif-bosutinib/">Bosulif</a> | Bosutinib | $199,137,491 | $369.42 | 1,732 | #220 |
| <a href="/drug/panzyga-immun-glob-g-igg-ifas-glycine/">Panzyga</a> | Immun Glob G(IgG)-Ifas/Glycine | $158,695,483 | $20.85 | 884 | #282 |
| <a href="/drug/vyndaqel-tafamidis-meglumine/">Vyndaqel</a> | Tafamidis Meglumine | $118,169,381 | $181.48 | 660 | #348 |
| Lorbrena | Lorlatinib | $75,625,415 | $492.21 | 605 | #477 |
| Xalkori | Crizotinib | $52,137,023 | $374.20 | 387 | #606 |
| Inflectra | Infliximab-Dyyb | $32,372,830 | $758.14 | 1,186 | #760 |
| Retacrit | Epoetin Alfa-Epbx | $24,529,471 | $208.88 | 12,187 | #883 |
| Ruxience | Rituximab-Pvvr | $16,542,688 | $74.73 | 791 | #1025 |
| Talzenna | Talazoparib Tosylate | $14,816,664 | $526.00 | 234 | #1073 |
| Eucrisa | Crisaborole | $10,407,692 | $12.15 | 5,637 | #1213 |
| Cibinqo | Abrocitinib | $9,784,290 | $184.57 | 347 | #1239 |
| Zirabev | Bevacizumab-Bvzr | $8,660,407 | $161.06 | 316 | #1289 |
| Toviaz | Fesoterodine Fumarate | $8,530,726 | $11.84 | 7,230 | #1298 |
| Sutent | Sunitinib Malate | $7,397,129 | $505.59 | 124 | #1355 |
| Geodon | Ziprasidone HCl | $6,284,899 | $27.91 | 359 | #1415 |
| Trazimera | Trastuzumab-Qyyp | $5,125,689 | $2,077.82 | 174 | #1485 |
| Levoxyl | Levothyroxine Sodium | $4,773,667 | $0.43 | 37,814 | #1512 |
| Cutaquig | Immun Glob G(IgG)-Hipp/Maltose | $4,278,989 | $33.27 | 48 | #1558 |
| Nyvepria | PEGfilgrastim-Apgf | $4,121,441 | $6,675.48 | 282 | #1568 |
| Bicillin L-A | Penicillin G Benzathine | $3,968,413 | $127.74 | 2,770 | #1587 |
| Daurismo | Glasdegib Maleate | $2,942,885 | $690.95 | 62 | #1706 |
| Elelyso | Taliglucerase Alfa | $2,779,778 | $905.17 | — | #1728 |
| Vizimpro | Dacomitinib | $2,774,626 | $535.02 | 35 | #1729 |
| Zavzpret | Zavegepant HCl | $2,306,719 | $194.76 | 999 | #1791 |
| Fragmin | Dalteparin Sodium,Porcine | $2,204,099 | $263.92 | 87 | #1809 |
| Procardia XL | Nifedipine | $2,006,051 | $9.40 | 652 | #1839 |
| Cytomel | Liothyronine Sodium | $2,005,765 | $2.03 | 2,302 | #1840 |
| Tikosyn | Dofetilide | $789,599 | $10.88 | 186 | #2191 |
| Celontin | Methsuximide | $695,875 | $4.73 | 217 | #2236 |
| Solu-Cortef | Hydrocortisone Sodium Succ/PF | $674,413 | $9.39 | 5,401 | #2247 |
| Eraxis | Anidulafungin | $593,317 | $87.34 | 146 | #2295 |
| Cardura | Doxazosin Mesylate | $465,074 | $5.99 | 232 | #2386 |
| Pfizerpen | Penicillin G Potassium | $442,151 | $8.55 | 419 | #2398 |
| Diflucan | Fluconazole | $229,457 | $36.89 | 279 | #2587 |
Source: CMS Medicare Part D Spending by Drug (data year 2023). Data as of June 2026.
Frequently asked questions
How much Medicare Part D spending does Pfizer US Pharm get?
In 2023, about $6,189,129,960 of Medicare Part D spending is attributed to Pfizer US Pharm across the 64 of its drugs tracked here. Its biggest is Ibrance at $2,020,903,604. This is gross program spending, not what patients pay. Source: CMS, data year 2023.
What is Pfizer US Pharm's top Medicare Part D drug?
Among the drugs tracked here, Pfizer US Pharm's highest Part D spending in 2023 is Ibrance at $2,020,903,604 (national rank #20 by total spend).
Is manufacturer attribution exact?
No. CMS may list multiple manufacturers per drug, and labeler relationships change over time. We attribute each drug to its primary listed manufacturer, so these rollups are indicative rather than definitive. Always check the underlying CMS file for a specific drug.
Keep exploring
Data: CMS Medicare Part D Spending by Drug (data year 2023), U.S. public domain. Aggregate program spending, not prices. Data as of June 2026. See our methodology and disclaimer.
Last updated: 2026-06-21